11/4
04:40 pm
opk
GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting [Yahoo! Finance]
Low
Report
GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting [Yahoo! Finance]
10/29
04:05 pm
opk
OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024
Medium
Report
OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024
10/29
03:46 pm
opk
GeneDx CEO on q3 earnings beat, genetic testing and pediatric health [CNBC]
Neutral
Report
GeneDx CEO on q3 earnings beat, genetic testing and pediatric health [CNBC]
10/29
11:58 am
opk
GeneDx climbs after profitability milestone in Q3 [Seeking Alpha]
Medium
Report
GeneDx climbs after profitability milestone in Q3 [Seeking Alpha]
10/29
11:42 am
opk
GeneDx climbs after profitability milestone in Q3 [Seeking Alpha]
Medium
Report
GeneDx climbs after profitability milestone in Q3 [Seeking Alpha]
10/24
11:25 am
opk
Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening [Yahoo! Finance]
Low
Report
Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening [Yahoo! Finance]
10/17
08:22 am
opk
With 50% ownership, OPKO Health, Inc. (NASDAQ:OPK) insiders have a lot riding on the company's future [Yahoo! Finance]
Low
Report
With 50% ownership, OPKO Health, Inc. (NASDAQ:OPK) insiders have a lot riding on the company's future [Yahoo! Finance]
10/11
10:40 am
opk
OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies [Yahoo! Finance]
Low
Report
OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies [Yahoo! Finance]
10/7
08:00 am
opk
ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program
Low
Report
ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program
10/2
01:49 pm
opk
Here's Why You Should Retain OPKO Health Stock in Your Portfolio [Yahoo! Finance]
Low
Report
Here's Why You Should Retain OPKO Health Stock in Your Portfolio [Yahoo! Finance]
9/26
08:17 am
opk
OPKO Health, Inc. (NASDAQ: OPK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Low
Report
OPKO Health, Inc. (NASDAQ: OPK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
9/23
08:00 am
opk
OPKO Health’s ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development
Low
Report
OPKO Health’s ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development
9/20
08:45 pm
opk
Greenberg Traurig Advises OPKO Health in $237.5 Million Asset Sale to Labcorp
Low
Report
Greenberg Traurig Advises OPKO Health in $237.5 Million Asset Sale to Labcorp
9/20
12:20 pm
opk
OPKO Health, Inc. (NASDAQ: OPK) had its "outperform" rating re-affirmed by analysts at Barrington Research. They now have a $2.25 price target on the stock.
Low
Report
OPKO Health, Inc. (NASDAQ: OPK) had its "outperform" rating re-affirmed by analysts at Barrington Research. They now have a $2.25 price target on the stock.
9/17
02:24 pm
opk
Labcorp Stock Gains From Its Latest Acquisition of BioReference Health [Yahoo! Finance]
Low
Report
Labcorp Stock Gains From Its Latest Acquisition of BioReference Health [Yahoo! Finance]
9/17
11:05 am
opk
OPKO Health, Inc. (NASDAQ: OPK) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $3.00 price target on the stock.
Low
Report
OPKO Health, Inc. (NASDAQ: OPK) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $3.00 price target on the stock.
9/17
08:02 am
opk
OPKO Health, Inc. (NASDAQ: OPK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Low
Report
OPKO Health, Inc. (NASDAQ: OPK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
9/4
10:58 am
opk
Down Syndrome Clinical Trials Review, 2024: Key Trends, Leading Companies, Latest Developments - Create Effective Counter Strategies to Gain a Competitive Advantage [Yahoo! Finance]
Low
Report
Down Syndrome Clinical Trials Review, 2024: Key Trends, Leading Companies, Latest Developments - Create Effective Counter Strategies to Gain a Competitive Advantage [Yahoo! Finance]
8/28
01:13 am
opk
Not Enough To Keep OPKO Health Flying [Seeking Alpha]
Low
Report
Not Enough To Keep OPKO Health Flying [Seeking Alpha]
8/9
04:13 pm
opk
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Neutral
Report
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
8/9
04:09 pm
opk
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates [Yahoo! Finance]
Neutral
Report
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates [Yahoo! Finance]
8/8
01:38 pm
opk
OPKO Health (OPK) Q2 Earnings Top Estimates, Gross Margin Down [Yahoo! Finance]
Low
Report
OPKO Health (OPK) Q2 Earnings Top Estimates, Gross Margin Down [Yahoo! Finance]
8/8
01:14 pm
opk
OPKO Health, Inc. (NASDAQ: OPK) had its price target raised by analysts at Barrington Research from $1.50 to $2.25. They now have an "outperform" rating on the stock.
Low
Report
OPKO Health, Inc. (NASDAQ: OPK) had its price target raised by analysts at Barrington Research from $1.50 to $2.25. They now have an "outperform" rating on the stock.
8/8
12:22 am
opk
Opko Health (OPK) Q2 2024 Earnings Call Transcript [Yahoo! Finance]
High
Report
Opko Health (OPK) Q2 2024 Earnings Call Transcript [Yahoo! Finance]
8/7
04:06 pm
opk
OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results
Medium
Report
OPKO Health Reports Second Quarter 2024 Business Highlights and Financial Results